Publications

Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.

Kumar P, Capodagli GC, Awasthi D, Shrestha R, Maharaja K, Sukheja P, Li S-G, Inoyama D, Zimmerman M, Liang HPin Ho et al..  2018.  Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.. mBio. 9(6)

Tiwari D, Park SWoong, Essawy MM, Dawadi S, Mason A, Nandakumar M, Zimmerman M, Mina M, Ho HPin, Engelhart CA et al..  2018.  Targeting protein biotinylation enhances tuberculosis chemotherapy.. Sci Transl Med. 10(438)

Chen C, Gardete S, Jansen RSander, Shetty A, Dick T, Rhee KY, Dartois V.  2018.  Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.. Antimicrob Agents Chemother. 62(5)

Park Y, Pacitto A, Bayliss T, Cleghorn LAT, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M et al..  2017.  Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.. ACS Infect Dis. 3(1):18-33.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WYee, Patel V, Beer D, Walker JR, Duraiswamy J et al..  2010.  A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.. Nat Commun. 1:57.